HCM HUTCHMED (China) Limited
Price Chart
Executive Summary
HUTCHMED reported mixed financial results for 2025, with a significant $457 million net income driven by a $416 million gain from the divestment of SHPL, but core oncology revenue declined 21% to $214.4 million. Despite a 5% increase in in-market sales and strong clinical progress across its pipeline — including positive Phase III data and regulatory approvals — underlying commercial performance in China weakened. The company maintains a robust $1.4 billion cash balance and provided 2026 oncology revenue guidance of $330–450 million, while advancing its novel ATTC platform into clinical trials.
Key Financial Metrics
Actionable Insight
Traders should focus on whether HUTCHMED can convert its strong clinical momentum and pipeline progress into sustained revenue growth in 2026, particularly in China. The stock may react positively to upcoming catalysts like SAFFRON and SANOVO topline data in 2026, but near-term pressure could persist if core product sales remain weak. Monitor for potential ATTC platform partnerships with multinational pharma companies as a value inflection point.
Key Facts
- Net income attributable to HUTCHMED was $456.9 million in 2025 (vs. $37.7 million in 2024), primarily due to a $415.8 million after-tax gain from the divestment of a 45% stake in SHPL.
- Total consolidated revenue declined 13% to $548.5 million, with oncology/immunology revenue down 21% to $285.5 million.
- In-market sales grew 5% to $524.7 million, led by 26% growth in FRUZAQLA® (ex-China) to $366.2 million, but offset by declines in ELUNATE®, SULANDA®, and ORPATHYS® in China.
- Oncology product revenue in China declined, though second-half 2025 sales grew 23% sequentially after commercial team restructuring.
- Positive late-stage clinical results: FRUSICA-2 (mPFS 22.2 vs 6.9 months in RCC), ESLIM-02 (sovleplenib met primary endpoint in wAIHA), and SACHI (savolitinib + TAGRISSO® in NSCLC).
- ATTC platform advanced: HMPL-A251 entered global Phase I/IIa in Dec 2025; HMPL-A580 trial initiated in Mar 2026; HMPL-A830 to enter clinic by year-end.
- 2026 oncology/immunology revenue guidance set at $330–450 million.
- Cash balance reached $1.37 billion, up from $836 million in 2024.
Financial Impact
Core oncology revenue declined by $57 million YoY, but one-time $416 million divestment gain inflated net income. 2026 oncology revenue guidance implies flat to modest growth (up to 58%) from 2025 levels, depending on execution.
Risk Factors
- Core oncology revenue continues to decline despite pipeline progress, raising concerns about commercial execution in China.
- 2025 net income is heavily inflated by a one-time divestment gain; underlying profitability remains under pressure.
- 2026 guidance range is wide and could reflect uncertainty in sales recovery or reliance on new approvals/partnerships.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249945 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
6-K
| $10.75 awaiting T+20 | awaiting T+20 | — | $10.96 (+1.95%) |
|
Jun 12, 2026
3d ago
|
Press Release
| $10.75 awaiting T+20 | awaiting T+20 | — | $10.96 (+1.95%) |
|
Apr 9, 2026
9w ago
|
Press Release
| $15.16 $13.43 | ▼ −11.41% | ▼ −18.98% | $10.96 (−27.70%) |
|
Mar 23, 2026
12w ago
|
Press Release
| $14.00 $14.87 | ▲ +6.21% | ▼ −1.21% | $10.96 (−21.71%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $13.85 $15.42 | ▲ +11.34% | ▲ +15.12% | $10.96 (−20.87%) |
|
Mar 4, 2026
14w ago
|
Press Release
| $13.65 $15.14 | ▲ +10.96% | ▲ +15.37% | $10.96 (−19.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access